VEGFA and prostate carcinoma: In order to assess the efficacy of SRPK1 inhibition by SPHINX on substrate phosphorylation, we previously showed that the treatment of PC3 prostate cancer cells with SPHINX led to reduced levels of phosphorylated SR proteins coinciding with increased expression of anti-angiogenic VEGFA (25, 29).